Q2 EPS Estimate for Cognition Therapeutics Raised by Analyst

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities research analysts at HC Wainwright lifted their Q2 2026 earnings estimates for shares of Cognition Therapeutics in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.06) for the quarter, up from their prior forecast of ($0.10). The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.26) EPS.

CGTX has been the subject of a number of other reports. Chardan Capital reiterated a “buy” rating and set a $4.00 target price on shares of Cognition Therapeutics in a research report on Friday, March 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Friday, March 27th. Finally, upgraded Cognition Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cognition Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Price Performance

Shares of CGTX opened at $1.18 on Wednesday. Cognition Therapeutics has a 1 year low of $0.22 and a 1 year high of $3.83. The company has a 50 day simple moving average of $1.07 and a two-hundred day simple moving average of $1.30. The firm has a market cap of $105.44 million, a P/E ratio of -4.92 and a beta of 1.81.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Investors Weigh In On Cognition Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its holdings in Cognition Therapeutics by 11,695.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock valued at $2,781,000 after acquiring an additional 2,042,815 shares during the period. Vanguard Group Inc. lifted its holdings in Cognition Therapeutics by 105.6% in the third quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock valued at $3,620,000 after acquiring an additional 1,377,263 shares during the period. Acadian Asset Management LLC lifted its holdings in Cognition Therapeutics by 814.1% in the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock valued at $422,000 after acquiring an additional 897,353 shares during the period. Millennium Management LLC acquired a new position in Cognition Therapeutics in the third quarter valued at approximately $757,000. Finally, Chescapmanager LLC lifted its holdings in Cognition Therapeutics by 98.1% in the third quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock valued at $1,346,000 after acquiring an additional 493,770 shares during the period. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.